Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Hong Kong · Delayed Price · Currency is HKD 7.03
+0.10 (1.44%)
Jun 1, 2026, 4:08 PM HKT
HKG:3613 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,513 | 1,612 | 1,525 | 1,731 | 1,556 | |
Revenue Growth (YoY) | -6.10% | 5.68% | -11.91% | 11.24% | 18.31% |
Cost of Revenue | 587.78 | 546.32 | 477.7 | 580.96 | 436.54 |
Gross Profit | 925.58 | 1,065 | 1,047 | 1,150 | 1,120 |
Selling, General & Admin | 390.41 | 492 | 410.29 | 341.68 | 341.68 |
Other Operating Expenses | -2.42 | -2.68 | -8.14 | -2.51 | -1.71 |
Operating Expenses | 449.58 | 491.27 | 423.33 | 345.65 | 347.49 |
Operating Income | 476 | 574.06 | 623.91 | 804.49 | 772.13 |
Interest Expense | -5.66 | -6.48 | -5.98 | -4.66 | -4.71 |
Interest & Investment Income | 47.04 | 57.67 | 73.12 | 20.59 | 4.38 |
Earnings From Equity Investments | -8.73 | 2.06 | -3.26 | -1.54 | 0.26 |
EBT Excluding Unusual Items | 508.65 | 627.3 | 687.79 | 818.88 | 772.06 |
Gain (Loss) on Sale of Investments | -4.89 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.93 | 2.47 | - | - | - |
Other Unusual Items | - | - | - | 7.09 | 6.33 |
Pretax Income | 504.69 | 629.77 | 687.79 | 825.96 | 778.39 |
Income Tax Expense | 87.83 | 100.61 | 97.2 | 134.67 | 126.85 |
Earnings From Continuing Operations | 416.86 | 529.17 | 590.59 | 691.29 | 651.54 |
Minority Interest in Earnings | -19.64 | -28.89 | -50.19 | -45.42 | -43.71 |
Net Income | 397.22 | 500.28 | 540.39 | 645.88 | 607.84 |
Net Income to Common | 397.22 | 500.28 | 540.39 | 645.88 | 607.84 |
Net Income Growth | -20.60% | -7.42% | -16.33% | 6.26% | 12.05% |
Shares Outstanding (Basic) | 837 | 837 | 837 | 837 | 837 |
Shares Outstanding (Diluted) | 837 | 837 | 837 | 837 | 837 |
EPS (Basic) | 0.47 | 0.60 | 0.65 | 0.77 | 0.73 |
EPS (Diluted) | 0.47 | 0.60 | 0.65 | 0.77 | 0.73 |
EPS Growth | -20.60% | -7.42% | -16.33% | 6.26% | 12.05% |
Free Cash Flow | 788.34 | -260.42 | 438.97 | 508.94 | 753.74 |
Free Cash Flow Per Share | 0.94 | -0.31 | 0.52 | 0.61 | 0.90 |
Dividend Per Share | 0.370 | 0.350 | 0.330 | 0.330 | 0.280 |
Dividend Growth | 5.71% | 6.06% | - | 17.86% | 16.67% |
Gross Margin | 61.16% | 66.10% | 68.67% | 66.44% | 71.95% |
Operating Margin | 31.45% | 35.62% | 40.91% | 46.47% | 49.62% |
Profit Margin | 26.25% | 31.04% | 35.44% | 37.31% | 39.06% |
Free Cash Flow Margin | 52.09% | -16.16% | 28.79% | 29.40% | 48.44% |
EBITDA | 495.52 | 592.88 | 640.57 | 818.84 | 786.5 |
EBITDA Margin | 32.74% | 36.79% | 42.01% | 47.30% | 50.54% |
D&A For EBITDA | 19.53 | 18.82 | 16.66 | 14.35 | 14.37 |
EBIT | 476 | 574.06 | 623.91 | 804.49 | 772.13 |
EBIT Margin | 31.45% | 35.62% | 40.91% | 46.47% | 49.62% |
Effective Tax Rate | 17.40% | 15.97% | 14.13% | 16.30% | 16.30% |
Advertising Expenses | 20.75 | 112.15 | 47.39 | 19.18 | 23.58 |